ISCO to Present New Data From Parkinson's Disease

ISCO to Present New Data From Parkinson's Disease Program at the American Neurological Association 2013 Annual Meeting. CARLSBAD, CA--(Marketwired - Sep 25, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies, announced today that its chief scientific officer, Dr. Ruslan Semechkin, will present the latest results from its Parkinson's disease program at the American Neurological Association's 2013 Annual Meeting October 13 - 15, 2013 in New Orleans, LA. Conducted in collaboration with the Sanford Burnham Medical Research Institute, the presentation will include new data and results from ISCO's first primate study, including an outline of neural stem cells' unique mechanism of action, data on the fate of the cells and a detailed analysis of the primate's immune response to the implantation. The presentation will be at the following session: Date: Monday, October 14, 2013 Time: 11:00 am - 7:00 pm Title: The Use of Neural Stem Cells for the Treatment of Parkinson's Disease in a Non-Human Primate Model ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (1) differentiate into dopaminergic neurons and (2) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new and revolutionary opportunity for the treatment of Parkinson's disease, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com. To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell Contact: International Stem Cell Corporation Dr. Simon Craw Executive Vice President Phone: 760-940-6383 Email: ir@intlstemcell.com Dr. Ruslan Semechkin Vice President, R&D Phone: 760-940-6383 Email: ras@intlstemcell.com http://finance.yahoo.com/news/international-s...00724.html